405937-99-7

Upstream product

• 201230-82-2 carbon monoxide 
• 151361-87-4 1-ethynyl-3,5-difluorobenzene 
• 32085-88-4 3,5-difluorobenzaldehyde 
• 75-07-0 acetaldehyde 
• 405937-98-6 (E)-3-(3,5-difluorophenyl)prop-2-en-1-ol 
• 2136-75-6 (triphenylphosphoranylidene)acetaldehyde 

Downstream Products

• 857722-08-8 1,3-Difluoro-5-((1E,3E)-4-phenyl-buta-1,3-dienyl)-benzene 
• 960006-18-2 3-{benzyl-[(E)-3-(3,5-difluoro-phenyl)-allyl]-amino}-propionitrile 
• 1013421-31-2 3-(3,5-difluorophenyl)-2-phenylisoxazolidin-5-one 
• 960006-19-3 rac-1-benzyl-4-(3,5-difluoro-benzyl)-pyrrolidine-3-carbonitrile 

Relevant academic research and scientific papers

INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE

Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.

RIPK1 INHIBITORS AND METHODS OF USE

The invention relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof. Formula (I) compounds act as RIPK1 inhibitors and may be useful in preventing, treating, or acting as a therapeutic agent against, diseases associated with RIPK1.

Selective Rhodium-Catalyzed Hydroformylation of Terminal Arylalkynes and Conjugated Enynes to (Poly)enals Enabled by a π-Acceptor Biphosphoramidite Ligand

The hydroformylation of terminal arylalkynes and enynes offers a straightforward synthetic route to the valuable (poly)enals. However, the hydroformylation of terminal alkynes has remained a long-standing challenge. Herein, an efficient and selective Rh-catalyzed hydroformylation of terminal arylalkynes and conjugated enynes has been achieved by using a new stable biphosphoramidite ligand with strong π-acceptor capacity, which affords various important E-(poly)enals in good yields with excellent chemo- and regioselectivity at low temperatures and low syngas pressures.

HETEROCYCLIC AMIDES AS RIP1 KINASE INHIBITORS

Disclosed are compounds having the formula: (I) wherein R1, R2, and R3 are as defined herein, and methods of making and using the same.

PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS

Novel 3-mono-, 3,4-di- and 3,4,4,-tri-substituted pyrrolidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on the activity of b

Regiospecific photoisomerization of fluorinated (E,E)-1,4-diphenyl-1,3- butadienes

Photoisomerization of five fluorinated E,E-1-(R-phenyl)-4-phenyl-1,3- butadienes in solution (R = 1: p-monofluoro, 2: m,m′-difluoro, 3: m,m′,p-trifluoro, 4: o,o′,m,m′-tetrafluoro, 5: o,o′,m,m′,p-pentafluoro) was investigated via direct irradiation. Our results indicated that cis-trans photoisomerization of the fluorinated 1,4-diphenyl-1,3-butadienes in the excited singlet state took place exclusively at the CC bonds closer to the fluorine substituents.

Quinoline derivatives as antibacterials

Aminopiperidine derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly in man.